Item 1.01 Entry into a Material Definitive Agreement.

On January 31, 2022, the Company entered into Amendment No. 3 (the "Amendment") to the Exclusive License and Collaboration Agreement, dated August 28, 2015, as amended on April 21, 2017, by and between the Parties.

Pursuant to the Amendment (and as a result of the termination of the Amended and Restated Collaboration Agreement, dated June 2, 2021 (the "U.S. Collaboration Agreement"), by and between the Parties, described under Item 1.02 hereof), Novartis will hold sole rights to commercialize Aimovig outside of the United States and Japan, Amgen will no longer pay royalties to Novartis on sales of Aimovig in the United States, and the Parties will no longer share the costs of commercialization of Aimovig in the United States. The Parties will continue to share development expenses worldwide.

The foregoing description of the Amendment and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Amendment, which is filed as Exhibit 10.1 hereof and which is incorporated herein by reference.

Item 1.02 Termination of a Material Definitive Agreement.

On January 31, 2022, concurrent with the entry into the Amendment described under Item 1.01 hereof, the Company terminated the U.S. Collaboration Agreement.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.





10.1      Amendment No. 3 to the Exclusive License and Collaboration Agreement,
        dated April 21, 2017, by and between Amgen Inc. and Novartis Pharma AG
        (portions of the exhibit have been omitted because they are both (i) not
        material and (ii) is the type of information that the Company treats as
        private or confidential.)

104     Cover Page Interactive Data File (embedded within the Inline XBRL
        document).






1   See Amgen's Annual Report on Form 10-K for the year ended December 31, 2020,
    Part IV-Note 19, Contingencies and commitments, to the Consolidated Financial
    Statements; and Notes 13 and 14, Contingencies and commitments, to the
    condensed consolidated financial statements in Amgen's Quarterly Report on
    Form 10-Q for the periods ended June 30, 2021 and September 30, 2021,
    respectively.


2   See Amgen's Current Report on Form 8-K filed on April 24, 2017; and Exhibits
    10.41 through 10.43, and 10.39 in Amgen's Quarterly Reports on Form 10-Q for
    the quarters ended June 30, 2017 and June 30, 2021, respectively.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses